A statistically significant association between DFNA5 CpG4 methylation percentage and human epidermal growth factor receptor 2 (HER2) amplification in 58 breast adenocarcinoma patients (45 without HER2 amplification and 13 with HER2 amplification) was found (p = 0.030; Table 1). Here, ERBB2 is linked to breast adenocarcinoma.